+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 12Years - 17Years
All Genders
ID05287126

Evaluating Etrasimod for Moderately to Severely Active Ulcerative Colitis in Adolescents Open-Label Study Assessing Safety, Pharmacokinetics, and Efficacy

Led by Pfizer · Updated on 2026-10-27

36

Participants Needed

47

Research Sites

212 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying etrasimod to evaluate its safety, how it works in the body, and its effects for treating adolescents aged 12 to less than 18 years with moderately to severely active ulcerative colitis. This is a phase 2, open-label study focused on treatment in this younger population. Participants who complete the first year of treatment may continue in a long-term extension phase lasting up to 4 more years, totaling 5 years of study involvement. Participants will take etrasimod as a tablet or granules by mouth once daily for up to 52 weeks during the initial treatment phase. Those who finish this period can join the long-term extension to continue receiving the drug under study conditions. No placebo or comparison group is used, as all participants receive etrasimod. Throughout the study, researchers will monitor participants regularly to assess clinical remission using the Modified Mayo Score at weeks 12 and 52, along with endoscopic and symptomatic improvements. Blood samples will be taken at specified times to measure drug levels in the body. Safety will be tracked by recording any adverse events. Participants may be followed for up to 5 years from enrollment, including the long-term extension period.

CONDITIONS

Brief Title

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here